ClinicalTrials.gg
RecruitingNCT03996824TREATGENEUpdated Sep 19, 2024

Study of Viral Transduction of Human Auditory Sensory Cells for the Development of Gene Therapy

An observational study in Hearing Loss, Sensorineural, sponsored by Institut Pasteur. Recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Institut Pasteur · Observational

From the registry’s dates

  • Started Feb 2019; still recruiting 7 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies in Hearing Loss, Sensorineural with a site in France — 14 open to participants now, 16 under way, none of them phase 3. Hearing Loss, Sensorineural · France.

Planned enrollment
5th of 10
100 · median 76
Started
2019
with 3 others
Observational
10 of 38
4 open now
Primary completion
2027-02
later than 11 of 15 live
Registered
8th of 38
by date
Lead sponsor
3 of 38
Institut Pasteur

Among the 38 studies in Hearing Loss, Sensorineural with a site in France, this one is the 5th largest by planned enrollment of the 10 observational ones that give a count, is one of 4 that started in 2019, is one of 10 observational ones, reaches primary completion later than 11 of the 15 other live ones, and was the 8th registered.

Hearing Loss, Sensorineural

346 studies on the registry are indexed under Hearing Loss, Sensorineural; 101 are open to participants now.

Browse Hearing Loss, Sensorineural studies →

Open to participants now

14 of the 38 studies in Hearing Loss, Sensorineural with a site in France are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 70 Hearing Loss, Sensorineural studies recruiting now, 39 (56%) set no upper age limit and 19 (27%) stop at 75 or younger; 26 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Hearing Loss, Sensorineural with a site in France, or all of them as a file.
02

Study summary

Gene therapy is a promising strategy to treat hearing loss and vestibular disorders, and Associated adenovirus (AAV) is shown as a good viral vector for inner ear therapy in animal models.

This study aims to study in vitro viral transduction of AAV in human inner ear cells, collected during non-conservative surgeries for vestibular schwannoma.

03

Conditions studied

  • Hearing Loss, Sensorineural
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients undergoing surgical resection of vestibular schwannoma.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient ≥ 18 years old
  • Operative indication for a non-conservative resection of vestibular schwannoma, decided by the surgeon in accordance with the patient
  • obtained
  • Patients with a french social protection (AME excluded)

Exclusion criteria

Exclusion Criteria:

  • Intravestibular or intra-cochlear extension of the tumor
  • Pregnant woman
  • Patient with administrative control
  • Medical
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • AAV viral transduction

    Collection of inner ear cells during a non-conservative surgical approach (translabyrinthine or transotic).

    Other: Peroperative collect of inner ear cells

Interventions

  • OtherPeroperative collect of inner ear cells

    After obtaining an informed consent during the preoperative medical visit, and if a non-conservative approach (translabyrinthine or transotic) is decided, the collect of inner ear cells will be performed during surgical approach. The sample will be collect in a sterile tube, and carried to the laboratory were it will be placed bon cell culture.

06

What researchers measure

Primary outcomes

  1. AAV transduction in inner ear cells

    The transduction will be measured with immunostaining techniques

    Time frame: 10 days

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2019 (actual). Primary completion is estimated for Feb 2027, 95 months after the start.

Of 42 observational studies under Hearing Loss, Sensorineural, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 13. This study's planned 95 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2019
First posted
Jun 25, 2019
StartActual
Feb 19, 2019
Primary completionEst.
Feb 18, 2027
CompletionEst.
Feb 18, 2027
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03996824
Lead sponsor
Institut Pasteur
Responsible party
Sponsor
First posted
Jun 25, 2019
Start date
Feb 19, 2019
Primary completion
Feb 18, 2027 (estimated)
Completion
Feb 18, 2027 (estimated)
Last update
Sep 19, 2024

Study contacts

Ghizlene Lahlou
Contact
ghizlene.lahlou@pasteur.fr
33 1 45688891
Saaid Safieddine
Contact
saaid.safieddine@pasteur.fr
Ghizlene Lahlou
study director · Institut Pasteur

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion